Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human.  biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II. 

Biotechnology

Life Sciences

Therapeutics

Kynexis

Kees Been

Thomas Gundelund Rasmussen

Christer Köhler

Thomas Rasmussen

Nancy Van Osselaer

Francis Mcmahon

Dennis Murphy

The Leadership Team at Kynexis is responsible for defining and steering the strategic vision and operational direction of the company. They guide the development and commercialization of KYN-5356, ensuring alignment with the company’s mission to advance precision therapeutics for brain diseases. The team oversees critical functions including clinical development, business strategy, and medical affairs, and ensures effective company-wide execution and stakeholder engagement.

Leadership Team

Clinical Development Team

Leadership Team

About

Team members

Other teams at Kynexis

Clinical Development Team